Paloma Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Paloma Partners’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4,473	Closed	-$276K	–	1224
2019 Q4	$276K	Buy	4,473 +1,268	+40%	+$84K	﹤0.01%	1800
2019 Q3	$234K	Buy	+3,205	New	+$240K	﹤0.01%	1673
2019 Q2	–	Sell	-4,164	Closed	-$294K	–	1705
2019 Q1	$294K	Buy	+4,164	New	+$245K	0.01%	1324
2018 Q4	–	Sell	-4,224	Closed	-$239K	–	1251
2018 Q3	$239K	Buy	+4,224	New	+$258K	﹤0.01%	1321
2017 Q2	–	Sell	-29,783	Closed	-$1.48M	–	2141
2017 Q1	$1.48M	Buy	29,783 +10,351	+53%	+$581K	0.02%	993
2016 Q4	$1.18M	Buy	+19,432	New	+$1.19M	0.01%	1071

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Paloma Partners's ANIP Position: Q1 2020 in Review

Paloma Partners sold out of ANI Pharmaceuticals (ANIP) in Q1 2020, closing a stake of 4,473 shares — an estimated $276K sold.

Paloma Partners first reported a position in ANIP in Q4 2016 and held it in 6 quarters. The position peaked at $1.48M in Q1 2017. 140 funds tracked by Wall St. Rank hold ANIP as of Q1 2020.

Paloma Partners reported no remaining ANI Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Paloma Partners sold 4,473 ANI Pharmaceuticals shares in Q1 2020, an estimated $276K.
Paloma Partners first reported a position in ANI Pharmaceuticals in Q4 2016 and held it in 6 quarters.
Paloma Partners's ANI Pharmaceuticals position peaked at $1.48M in Q1 2017.
140 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.